Figure S3 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418982

2023-01-01

Abstract:RORC Sensitizes Bladder Cancer Cells to Cisplatin

What problem does this paper attempt to address?

Figure S2 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418985.v1

2023-01-01

Abstract:RORC Regulates Proliferation and Apoptosis via inhibiting Glycolysis in Bladder Cancer Cells
Figure S4 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418979

2023-01-01

Abstract:PD-L1 Attenuates Anti-tumor effect of RORC in Bladder cancer
Figure S5 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Qi Zhou,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yan Zhu,Yi Shen,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418976

2023-01-01

Abstract:Influence of RORC on the growth and proliferation of bladder cancer in vivo
Figure S6 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Qi Zhou,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yan Zhu,Yi Shen,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418973.v1

2023-01-01

Abstract:The associations among the expression of PD-L1, ITGB6, STAT3 and p-STAT3 and survival of Bladder Urothelial Cancer Patients
Data from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.c.6510267.v1

2023-01-01

Abstract:AbstractRetinoic acid–related orphan receptor C (RORC) is a member of the nuclear orphan receptor family and performs critical regulatory functions in cell proliferation, metastasis, and chemoresistance in various types of malignant tumors. Here we showed that expression of RORC is lost in tumor tissues of bladder cancer patients. Enhanced expression of RORC suppressed cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis in vitro and in vivo. RORC bound the promoter region of programmed death ligand-1 (PD-L1) and negatively regulated PD-L1 expression. PD-L1 directly interacted with integrin β6 (ITGB6) and activated the ITGB6/FAK signaling pathway. RORC prevented the nuclear translocation of STAT3 via suppression of the PD-L1/ITGB6 signaling pathway, which further inhibited bladder cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis. These findings reveal that RORC regulates bladder cancer cell proliferation, glucose metabolism, and chemoresistance by participating in the PD-L1/ITGB6/STAT3 signaling axis. Moreover, this new understanding of PD-L1 signaling may guide the selection of therapeutic targets to prevent tumor recurrence.Significance:These findings suggest that RORC-mediated regulation of a PD-L1/ITGB6/FAK/STAT3 signaling axis in bladder cancer provides several potential therapeutic targets to prevent tumor progression.
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.CAN-18-3842

2019-05-15

Abstract:Retinoic acid-related orphan receptor C (RORC) is a member of the nuclear orphan receptor family and performs critical regulatory functions in cell proliferation, metastasis, and chemoresistance in various types of malignant tumors. Here we showed that expression of RORC is lost in tumor tissues of bladder cancer patients. Enhanced expression of RORC suppressed cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis in vitro and in vivo. RORC bound the promoter region of programmed death ligand-1 (PD-L1) and negatively regulated PD-L1 expression. PD-L1 directly interacted with integrin β6 (ITGB6) and activated the ITGB6/FAK signaling pathway. RORC prevented the nuclear translocation of STAT3 via suppression of the PD-L1/ITGB6 signaling pathway, which further inhibited bladder cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis. These findings reveal that RORC regulates bladder cancer cell proliferation, glucose metabolism, and chemoresistance by participating in the PD-L1/ITGB6/STAT3 signaling axis. Moreover, this new understanding of PD-L1 signaling may guide the selection of therapeutic targets to prevent tumor recurrence. SIGNIFICANCE: These findings suggest that RORC-mediated regulation of a PD-L1/ITGB6/FAK/STAT3 signaling axis in bladder cancer provides several potential therapeutic targets to prevent tumor progression.
Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418970

2023-01-01

Abstract:Supplementary Figure Legends
Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Yunfei Wu,Zhijie Xu,Guanghou Fu,Xiaoyi Chen,Junjie Tian,Hairong Cai,Peng Jiang,Baiye Jin

DOI: https://doi.org/10.1016/j.tranon.2024.101942

IF: 4.803

2024-01-01

Translational Oncology

Abstract:Cisplatin resistance plays a significant role in the dismal prognosis and progression of muscle-invasive bladder cancer (MIBC). However, the strategies to predict prognosis and cisplatin resistance are inefficient, and it remains unclear whether cisplatin resistance is associated with tumor immunity. In this study, we integrated the transcriptional data from cisplatin-resistant cell lines and a TCGA-MIBC cohort to establish cisplatin-resistance-related cluster classification and a cisplatin-resistance-related gene risk score (CRRGRS). Kaplan–Meier survival curves showed that compared with those in low CRRGRS group, MIBC patients belonging to high CRRGRS group had worse prognosis in TCGA-MIBC cohort and external GEO cohorts. Meanwhile, CRRGRS was able to help forecast chemotherapy and immunotherapy response of MIBC patients in the TGCA cohort and IMvigor210 cohort. Moreover, compared with the low CRRGRS group, the high CRRGS group possessed a relatively immunosuppressive “cold tumor” phenotype with a higher tumor immune dysfunction and exclusion (TIDE) score, ESTIMATE score, stromal score and immune score and a lower immunophenoscore (IPS) score. The upregulated expression levels of immune checkpoint genes, including PD-1, PD-L1 and CTLA4, in the high CRRGRS group also further indicated that a relative immunosuppressive tumor microenvironment may exist in MIBC patients belonging to high CRRGRS group. In addition, we integrated CRRGRS and clinical characteristics with prognostic value to develop a nomogram, which could help forecast overall survival of MIBC patients. Furthermore, DIAPH3 was identified as a regulator of proliferation and cisplatin resistance in MIBC. The expression of DIAPH3 was increased in cisplatin-resistant cell lines and chemotherapy-unsensitive people. Further mechanism exploration revealed that DIAPH3 facilitated tumor proliferation and cisplatin resistance by regulating the NF-kB and epithelial-mesenchymal transition (EMT) pathways. In conclusion, the comprehensive investigations of CRRGRS increased the understanding of cisplatin resistance and provided promising insights to restrain tumor growth and overcome chemoresistance by targeting DIAPH3.
Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells

Ruiqi Lu,Gang Zhao,Yulong Yang,Zhaoyan Jiang,Jingli Cai,Hai Hu

DOI: https://doi.org/10.1177/1533033819864311

2019-01-01

Abstract:Cisplatin is widely used as the standard gastric cancer treatment, but the relapse and metastasis are common as intrinsic or acquired drug resistance. CD133 has been widely known to be associated with chemoresistance in various cancer cells. In this study, we focused on investigating the function and mechanism of CD133 underlying cisplatin resistance in gastric cancer cell line KATO-III. We detected CD133 expression by using quantitative real-time polymerase chain reaction and Western blot and found that expression of CD133 was upregulated in cisplatin resistance of KATO-III cells (Cis-KATO-III) compared with KATO-III cells, indicating the role of CD133 in regulating cisplatin resistance of KATO-III cells. Then we sorted the Cis-KATO-III cells into CD133-positive (CD133 + ) pools and measured the proliferation and apoptosis after the cell is transfected with pc-CD133 and sh-CD133 by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay and flow cytometry. The results showed that the inhibition of CD133 inhibited the cell viability and promoted the cell apoptosis after cisplatin treatment. Furthermore, we found that inhibition of CD133 downregulated the expression of PI3K/AKT and promoted the expression of mammalian target of rapamycin, thus inhibited the autophagic activity in the Cis-KATO-III cells after cisplatin treatment. Besides, we also verified the effects of CD133 in vivo. The results indicated that inhibition of CD133 enhanced the Cis-KATO-III cell sensitivity to cisplatin by regulating PI3K/AKT/mTOR signaling pathway. In summary, our data provide new insight that CD133 activates the PI3K/AKT/mTOR signaling transduction pathway, resulting in activation of autophagy and cisplatin resistance of Cis-KATO-III cells. These results may offer a novel therapeutic target in cisplatin-resistant gastric cancer.

oncology
Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth

Weidong Peng,Haojie Zhang,Mingwei Yin,Dejie Kong,Liping Kang,Xinkun Teng,Jingjing Wang,Zhimin Chu,Yating Sun,Pengpeng Long,Chengying Cui,Bin Lyu,Jinzhi Zhang,Han Xiao,Mingqing Wu,Yongqiang Wang,Yang Li

DOI: https://doi.org/10.1038/s41389-024-00529-y

2024-07-27

Oncogenesis

Abstract:Bladder cancer is characterized by aberrant activation of the phosphatidylinositol-3-OH kinase (PI3K) signaling, underscoring the significance of directing therapeutic efforts toward the PI3K pathway as a promising strategy. In this study, we discovered that PI3K serves as a potent therapeutic target for bladder cancer through a high-throughput screening of inhibitory molecules. The PI3K inhibitor demonstrated a robust anti-tumor efficacy, validated both in vitro and in vivo settings. Nevertheless, the feedback activation of JAK1-STAT3 signaling reinstated cell and organoid survival, leading to resistance against the PI3K inhibitor. Mechanistically, the PI3K inhibitor suppresses PTPN11 expression, a negative regulator of the JAK-STAT pathway, thereby activating STAT3. Conversely, restoration of PTPN11 enhances the sensitivity of cancer cells to the PI3K inhibitor. Simultaneous inhibition of both PI3K and STAT3 with small-molecule inhibitors resulted in sustained tumor regression in patient-derived bladder cancer xenografts. These findings advocate for a combinational therapeutic approach targeting both PI3K and STAT3 pathways to achieve enduring cancer eradication in vitro and in vivo, underscoring their promising therapeutic efficacy for treating bladder cancer.
Figure S4 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Shu-Xiong Zeng,Yanjun Zhu,Ai-Hong Ma,Weimin Yu,Hongyong Zhang,Tzu-Yin Lin,Wei Shi,Clifford G. Tepper,Paul T. Henderson,Susan Airhart,Jian-Ming Guo,Chuan-Liang Xu,Ralph W. deVere White,Chong-Xian Pan

DOI: https://doi.org/10.1158/1078-0432.22468512

2023-01-01

Abstract:Ki67 and cleaved caspase 3 expression in BL0440 tumors
SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis

Yang Cao,Ping Li,Haicun Wang,Lei Li,Quanwang Li

DOI: https://doi.org/10.1002/cam4.3728

IF: 4.711

2021-02-01

Cancer Medicine

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Cisplatin is an extensively used chemotherapy agent for lung cancer, but its drug resistance serves as a huge obstacle for chemotherapy failure of lung cancer patients. Hence, researchers aimed to determine role of sirtuin 3 (SIRT3) considering its action in cisplatin resistance of lung cancer.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The expression patterns of SIRT3, FOXO3, and CDT1 were determined using RT‐qPCR and Immunoblotting in lung cancer. Immunofluorescence and Co‐IP were adopted to detect co‐localization and interaction of FOXO3 and CDT1. Loss‐ and gain‐function assays were conducted to determine roles of SIRT3, FOXO3, and CDT1 in resulting pathological changes, while biological behavior of cells was determined using a combination of CCK‐8, flow cytometry, colony formation, and Transwell assays. The effects of SIRT3 and CDT1 were determined in the nude mice xenografted with the tumor. The proliferation‐, angiogenesis‐, and apoptosis‐associated factors levels were determined using Immunoblotting.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>SIRT3, FOXO3, and CDT1 expression was suppressed in the lung cancer tissues and cells. FOXO3 positively regulates the CDT1 expression pattern and SIRT3 elevation inhibits FOXO3 at the acetylated level, thus, elevating FOXO3 expression. The elevation of SIRT3, FOXO3, or CDT1 inhibited cell cisplatin resistance of lung cancer cells as well as inhibited viability, proliferation, and invasion <i>in vitro</i>. In vivo experiments, SIRT3 depletion elevated Ki‐67 and VEGFA levels, but downregulated cleaved caspase 3 level. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Collectively, overexpressed SIRT3 elevates expression of FOXO3a/CDT1 axis, thus, contributing to enhanced sensitivity of lung cancer cells.</p></section>

oncology
Unveiling the role of RAC3 in the growth and invasion of cisplatin‐resistant bladder cancer cells

Haodong Li,Hongxuan Ma,JianHua Ma,Fei Qin,Siqi Fan,Shaopeng Kong,Sitao Zhao,Jianguo Ma

DOI: https://doi.org/10.1111/jcmm.18473

2024-06-09

Journal of Cellular and Molecular Medicine

Abstract:Abstract Bladder cancer is one of the most prevalent cancers worldwide, and its morbidity and mortality rates have been increasing over the years. However, how RAC family small GTPase 3 (RAC3) affects the proliferation, migration and invasion of cisplatin‐resistant bladder cancer cells remains unclear. Bioinformatics techniques were used to investigate the expression of RAC3 in bladder cancer tissues. Influences of RAC3 in the grade, stage, distant metastasis, and survival rate of bladder cancer were also examined. Analysis of the relationship between RAC3 expression and the immune microenvironment (TIME), genomic mutations, and stemness index. In normal bladder cancer cells (T24, 5637, and BIU‐87) and cisplatin‐resistant bladder cancer cells (BIU‐87‐DDP), the expression of RAC3 was detected separately with Western blotting. Plasmid transfection was used to overexpress or silence the expression of RAC3 in bladder cancer cells resistant to cisplatin (BIU‐87‐DDP). By adding activators and inhibitors, the activities of the JNK/MAPK signalling pathway were altered. Cell viability, invasion, and its level of apoptosis were measured in vitro using CCK‐8, transwell, and flow cytometry. The bioinformatics analyses found RAC3 levels were elevated in bladder cancer tissues and were associated with a poor prognosis in bladder cancer. RAC3 in BIU‐87‐DDP cells expressed a higher level than normal bladder cancer cells. RAC3 overexpression promoted BIU‐87‐DDP proliferation. The growth of BIU‐87‐DDP cells slowed after the knockdown of RAC3, and RAC3 may have had an impact on the activation of the JNK/MAPK pathway.

cell biology,medicine, research & experimental
Suppl. Figure 2 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy

Qinghai Zeng,Jianye Liu,Peng Cao,Jingjing Li,Xiaoming Liu,Xiaodong Fan,Ling Liu,Yan Chen,Wei Xiong,Jigang Li,Bo Hu,Yan Zhu,Fei Yang,Jun Hu,Ming Zhou,Yanhong Zhou,Qiong Zou,Jianda Zhou,Ke Cao

DOI: https://doi.org/10.1158/1078-0432.22466948

2023-01-01

Abstract:(A) The mutation sites in the REDD1 3'UTR reporter construct. (B) The cytotoxicity test of Taxol in T24 and RT4 cells. Cell proliferation was determined in T24 and RT4 cells using the CCK-8 method.
Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy

Deyi Zhang,Ryan M. Reyes,Erica Osta,Suresh Kari,Harshita B. Gupta,Alvaro S. Padron,Anand V. R. Kornepati,Aravind Kancharla,Xiujie Sun,Yilun Deng,Bogang Wu,Ratna Vadlamudi,Rong Li,Robert S. Svatek,Tyler J. Curiel

DOI: https://doi.org/10.1002/cam4.3739

IF: 4.711

2021-02-24

Cancer Medicine

Abstract:Tumor cell‐intrinsic programmed death‐ligand 1 (PD‐L1) signals mediate immunopathologic effects in breast, colon, and ovarian cancers and in melanomas, but bladder cancer (BC) effects are unreported. We show here that BC cell‐intrinsic PD‐L1 signals in mouse MB49 and human RT4, UM‐UC3, and UM‐UC‐14 BC cells regulate important pathologic pathways and processes, including effects not reported in other cancers. α‐PD‐L1 antibodies reduced BC cell proliferation in vitro, demonstrating direct signaling effects. BC cell‐intrinsic PD‐L1 promoted mammalian target of rapamycin complex 1 (mTORC1) signals in vitro and augmented in vivo immune‐independent cell growth and metastatic cancer spread, similar to effects we reported in melanoma and ovarian cancer. BC cell‐intrinsic PD‐L1 signals also promoted basal and stress‐induced autophagy, whereas these signals inhibited autophagy in melanoma and ovarian cancer cells. BC cell‐intrinsic PD‐L1 also mediated chemotherapy resistance to the commonly used BC chemotherapy agents cis‐platinum and gemcitabine and to the mTORC1 inhibitor, rapamycin. Thus, BC cell‐intrinsic PD‐L1 signals regulate important virulence and treatment resistance pathways that suggest novel, actionable treatment targets meriting additional studies. As a proof‐of‐concept, we showed that the autophagy inhibitor chloroquine improved cis‐platinum treatment efficacy in vivo, with greater efficacy in PD‐L1 null versus PD‐L1‐replete BC.

oncology
Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer

Hanyuan Gao,Yanru Qiu,Xueqin Zheng,Tianwen Xu,Guangjian Liu

DOI: https://doi.org/10.3389/fonc.2024.1466319

2024-09-16

Abstract:Background: Bladder cancer (BLCA) is a prevalent urinary tract malignancy with a high propensity for recurrence and chemoresistance. The molecular mechanisms underlying its progression and response to therapy have not been fully elucidated. Methods: We conducted a multifaceted analysis, integrating immunohistochemical (IHC) staining, bioinformatics evaluation using TCGA and CCLE databases, and in vitro assays using the BLCA cell lines 5637 and T24. RAC3 expression was assessed relative to clinical and pathological features. Functional enrichment analyses and gene set enrichment analysis (GSEA) were performed to identify associated biological processes and pathways. The impacts of RAC3 on cell proliferation, migration, invasion, and the immune microenvironment were evaluated using siRNA knockdown, CCK-8, Transwell, wound healing and colony formation assays. Results: Elevated RAC3 expression was significantly correlated with an advanced tumor stage, lymph node metastasis, and poor prognosis for BLCA patients. The functional enrichment analysis implicated RAC3 in immune cell infiltration and immune checkpoint mechanisms. Notably, RAC3 knockdown significantly reduced the proliferative, migratory, and invasive capabilities of BLCA cells. These effects were reversed by the overexpression of RAC3. Additionally, RAC3 expression was linked to chemoresistance, with high RAC3 expression predicting resistance to certain therapeutic agents. The TIDE algorithm indicated that RAC3 expression could be a predictive biomarker for the immunotherapy response. Conclusion: RAC3 was identified as a potential therapeutic target and biomarker of BLCA, as its expression significantly influenced tumor progression, the immune response, and chemosensitivity. Targeting RAC3 may provide a novel strategy for the management of BLCA, particularly for patients resistant to conventional therapies. Further research is essential to elucidate the detailed mechanisms of RAC3 in BLCA and explore its clinical application in precision medicine.
Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment

Lang He,Xiaoshan Wang,Kang Liu,Xun Wu,Xuemei Yang,Guiqin Song,Bing Zhang,Liming Zhong

DOI: https://doi.org/10.1016/j.gene.2018.12.028

IF: 3.913

2019-04-05

Gene

Abstract:Background: Chemoresistance to cisplatin in lung cancer treatment remains prevalent. Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma. Methods: We performed an RNA-Sequencing (RNA-Seq) analysis to identify differentially expressed genes in ERCC1-deficient cells co-treated with cisplatin and sodium glycididazole (CMNa). Differentially expressed genes and the hub genes in the cisplatin/CMNa-treated cells were identified by systematic network analysis. Oncomine expression analysis was also performed to evaluate the clinical implication of the identified hub gene. Results: Platelet-derived growth factor receptor (PDGF/PDGFR) and focal adhesion genes were downregulated in ERCC1-defective non-small cell lung cancer (NSCLC) cells undergoing combined cisplatin/CMNa treatment. Consistent with the finding, cell migration was reduced in these cells. PDGFRB was identified as the hub gene in the process by differential expressed gene network analysis. Importantly, elevated PDGFRB level was observed in advanced lung adenocarcinoma patients with metastases. Conclusion: PDGF/PDGFR and focal adhesion signaling may serve as another mechanism in addition to ERCC1-mediated cisplatin-resistance in lung adenocarcinoma. Multiple pro-invasion/pro-migration/proliferation and DNA damage repair pathways may be integrated to confer growth advantages on tumor cells.
TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling

Xiaoju Ding,Yunjie Jin,Xiaokai Shi,Yidi Wang,Zhibo Jin,Lei Yin,Shenglin Gao,Yibo Lei,Jinjian Yang

DOI: https://doi.org/10.1016/j.bcp.2024.116172

Abstract:The enzyme tryptophan 2,3-dioxygenase (TDO2) has been implicated in the dysregulation across a variety of human cancers. Despite this association, the implications of TDO2 in the progression of bladder cancer have eluded thorough understanding. In this study, we demonstrate that TDO2 expression is notably elevated in bladder cancer tissues and serves as an unfavorable prognostic factor for overall survival. Through a series of biological functional assays, we have determined that TDO2 essentially enhances cell proliferation, metastatic potential, and imparts a decreased sensitivity to the chemotherapeutic agent cisplatin. Our mechanistic investigations reveal that TDO2 augments aryl hydrocarbon receptor (AhR) signaling pathways and subsequently upregulates the expression of SPARC and FILIP1L. Importantly, we have identified a positive correlation between TDO2 levels and the basal/squamous subtype of bladder cancer, and we provide evidence to suggest that TDO2 expression is modulated by the tumor suppressors RB1 and TP53. From a therapeutic perspective, we demonstrate that the targeted inhibition of TDO2 with the molecular inhibitor 680C91 markedly attenuates tumor growth and metastasis while concurrently enhancing the efficacy of cisplatin. These findings open a new therapeutic avenue for the management of bladder cancer.
Figure S5 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Shu-Xiong Zeng,Yanjun Zhu,Ai-Hong Ma,Weimin Yu,Hongyong Zhang,Tzu-Yin Lin,Wei Shi,Clifford G. Tepper,Paul T. Henderson,Susan Airhart,Jian-Ming Guo,Chuan-Liang Xu,Ralph W. deVere White,Chong-Xian Pan

DOI: https://doi.org/10.1158/1078-0432.22468509

2023-01-01

Abstract:p-p70S6K, pS6 and p-ERK expression in bladder cancer cells treated with pictilisib
Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells

Gizem Ozgun,Tutku Yaras,Burcu Akman,Gülden Özden-Yılmaz,Nick Landman,Gökhan Karakülah,Maarten van Lohuizen,Serif Senturk,Serap Erkek-Ozhan

DOI: https://doi.org/10.1038/s41417-024-00725-3

IF: 5.854

2024-01-18

Cancer Gene Therapy

Abstract:The highly mutated nature of bladder cancers harboring mutations in chromatin regulatory genes opposing Polycomb-mediated repression highlights the importance of targeting EZH2 in bladder cancer. Furthermore, the critical role of the retinoic acid signaling pathway in the development and homeostasis of the urothelium, and the anti-oncogenic effects of retinoids are well established. Therefore, our aim is to simultaneously target EZH2 and retinoic acid signaling in bladder cancer to potentiate the therapeutic response. Here we report that this coordinated targeting strategy stimulates an anti-oncogenic profile, as reflected by inducing a synergistic reduction in cell viability that was associated with increased apoptosis and cell cycle arrest in a cooperative and orchestrated manner. This study characterized anti-oncogenic transcriptional reprogramming centered on the transcriptional regulator CHOP by stimulating the endoplasmic reticulum stress response. We further portrayed a molecular mechanism whereby EZH2 maintains H3K27me3-mediated repression of a subset of genes involved in unfolded protein responses, reflecting the molecular mechanism underlying this co-targeting strategy. These findings highlight the importance of co-targeting the EZH2 and retinoic acid pathway in bladder cancers and encourage the design of novel treatments employing retinoids coupled with EZH2 inhibitors in bladder carcinoma.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology

Figure S3 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Figure S2 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Figure S4 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Figure S5 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Figure S6 from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Data from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells

Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth

Figure S4 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

SIRT3 promotion reduces resistance to cisplatin in lung cancer by modulating the FOXO3/CDT1 axis

Unveiling the role of RAC3 in the growth and invasion of cisplatin‐resistant bladder cancer cells

Suppl. Figure 2 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy

Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy

Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer

Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment

TDO2 promotes bladder cancer progression via AhR-mediated SPARC/FILIP1L signaling

Figure S5 from the Phosphatidylinositol 3-Kinase Pathway As a Potential Therapeutic Target in Bladder Cancer

Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells